SINGULA™
Oncology (e.g., NSCLC)
Clinical ValidationActive
Key Facts
About Cellworks
Founded in 2005 and headquartered in San Francisco, Cellworks has developed a sophisticated computational biology platform that simulates disease networks to predict therapy responses. The company serves both pharmaceutical clients (through its Precision Pharma offerings) and clinicians/patients (through its Personalized Therapy Decision Support products like SINGULA™ and VENTURA™). Its approach aims to de-risk drug development, optimize clinical trial design, and provide actionable treatment recommendations for refractory cancer patients by evaluating over 20 million potential drug combinations against a patient's unique molecular profile.
View full company profileTherapeutic Areas
Other Oncology (e.g., NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| HDPCR for Tumor Profiling | ChromaCode | Commercial |